EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

HLA evolutionary divergence score after donor lymphocyte infusion following allogeneic hematopoietic stem cell transplantation

Sophie Le Grand iD, Juliette Villemonteix, Etienne Daguindau iD, Marylise Fort, Sophie Caillat-Zucman iD, Vincent Allain iD, Anne Dormoy, Veronique De Mas, Eric Delabesse iD, Christian Recher iD, Regis Peffault de Latour iD, Nicolas Vallet iD und 3 weitere

HemaSphere · 2025-02 · 9 (2)

DOI: 10.1002/hem3.70088 ↗

Kurz gefasst

Fachartikel in der Zeitschrift HemaSphere, online erschienen am 13.02.2025. Verfasst von Sophie Le Grand und 14 weiteren Autor:innen. Beteiligte Einrichtung: Hematology Department Centre Hospitalo-universitaire (CHU) de Toulouse, Institut Universitaire du Cancer de Toulouse-Oncopole (IUCT-O), Université de…. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Donor lymphocyte infusion (DLI) prevents acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) relapses following hematopoietic stem cell transplantation. Given the life‐threatening toxicities such as graft versus host disease (GVHD), the identification of variables associated with response without toxicities is warranted. We hypothesized that HLA evolutionary divergence (HED), defined by the diversity between two given alleles of the same HLA gene, may be such a factor. A retrospective multicenter case‐control study was conducted to evaluate the outcomes of pre‐emptive (preDLI) and prophylactic DLI (proDLI) regarding their HED score, in AML or MDS patients. DLI‐treated patients were matched with controls (1:2 matched) from French transplantation centers according to hospital, hemopathy, donor type, and risk classification. In total, 201 patients were included ( N = 147 in the preDLI group, N = 54 in the proDLI group). Relapse‐free survival was significantly better in the preDLI group (hazard ratio [HR] = 0.23, 95% confidence interval [CI]: 0.14–0.55, p < 0.001) than in controls. However, this benefit was offset by a higher incidence of severe GVHD (HR = 4.88, 95% CI: 2.30–10.32, p < 0.001). HED A, B, C, DQA1, DQB1, DPB1, and DRB1 were calculated for 65 DLI‐treated patients. High‐class II HED was significantly associated with higher GVHD and relapse‐free survival (GRFS, HR = 0.33, 95% CI: 0.20–0.77, p = 0.005). Specific DQAB associations directly improved GRFS (HR = 0.23, 95% CI: 0.09–0.58, p = 0.004). In conclusion, screening the class II HED score identifies patients eligible for DLI treatment who will benefit the most from this strategy.

Autor:innen und Institutionen

  • Hematology Department Centre Hospitalo-universitaire (CHU) de Toulouse, Institut Universitaire du Cancer de Toulouse-Oncopole (IUCT-O), Université de Toulouse, UPS Toulouse France.
  • Immunology and Histocompatibility Laboratory Assistance Publique des Hôpitaux de Paris (AP-HP), Saint Louis Hospital Paris France.
  • Service d'Hématologie, Jean Minjoz Hospital Besançon France.
  • Immunology Laboratory Centre Hospitalo-universitaire (CHU) de Toulouse, Université de Toulouse, UPS Toulouse France.
  • INSERM UMR 1342 Saint Louis Hospital, Université de Paris Cité Paris France.
  • Etablissement Français du sang, Hôpital Jean Minjoz Besançon France.

ORCID-Profile: Sophie Le Grand, Etienne Daguindau, Sophie Caillat-Zucman, Vincent Allain, Eric Delabesse, Christian Recher, Regis Peffault de Latour, Nicolas Vallet, David Michonneau, Sarah Guenounou

Zitieren

APA

Le Grand, S., Villemonteix, J., Daguindau, E., Fort, M., Caillat-Zucman, S., Allain, V., Dormoy, A., De Mas, V., Delabesse, E., Recher, C., Peffault de Latour, R., Vallet, N., Michonneau, D., Guenounou, S., & Huynh, A. (2025). HLA evolutionary divergence score after donor lymphocyte infusion following allogeneic hematopoietic stem cell transplantation. HemaSphere, 9(2). https://doi.org/10.1002/hem3.70088

Vancouver

Le Grand S, Villemonteix J, Daguindau E, Fort M, Caillat-Zucman S, Allain V, et al. HLA evolutionary divergence score after donor lymphocyte infusion following allogeneic hematopoietic stem cell transplantation. HemaSphere. 2025;9(2). doi:10.1002/hem3.70088

BibTeX
@article{LeGrand2025,
  author = {Le Grand, Sophie and Villemonteix, Juliette and Daguindau, Etienne and Fort, Marylise and Caillat-Zucman, Sophie and Allain, Vincent and Dormoy, Anne and De Mas, Veronique and Delabesse, Eric and Recher, Christian and Peffault de Latour, Regis and Vallet, Nicolas and Michonneau, David and Guenounou, Sarah and Huynh, Anne},
  title = {HLA evolutionary divergence score after donor lymphocyte infusion following allogeneic hematopoietic stem cell transplantation},
  journal = {HemaSphere},
  year = {2025},
  volume = {9},
  number = {2},
  doi = {10.1002/hem3.70088}
}
Kostenlos starten →